Seite wählen

Serotype Ad19a/64

Overcome the drawbacks of commonly available Ad serotypes

Ad19a/64, the first openly accessible subtype D adenovirus. The vector is superior in its action to transduce human-derived cells (myoblasts and myotubes) much more efficiently when compared to Ad5.  It also possesses CAR independent binding properties, targeting a sialic acid-dependent receptors.

Ad19a/64 will help you

  • Target new cell types/tissue due to its unique receptor affinities.
  • Utilze its low pre-immunization rates within the human populationwhen developing Ad based vaccination.

Whenever you experience with Ad5

  • Limitations due to CAR dependant transduction or
  • Pre-existing anti-adenovirus immunity against in Ad5 in humans.

contact SIRION Biotech for its unique Ad19a/64-BAC-technology. SIRION Biotech is actively seeking strategic alliances for the development of commercial use of Ad19a/64 .The offered material is license-free for research only, any and all other uses require an explicit approval from Sirion Biotech GmbH.

Human Myoblasts

Transduction of myoblasts with Ad5-EGFP (Ad5) and Ad19a/64-EGFP (Ad19a). Primary myoblasts of human, ape, pig and mouse origin were transduced with 1250 VP/cell (open columns). 2500 VP/cell (shaded columns) and 12500 VP/cell (solid columns), respectively, and GFP expression was quantified after 48 hr. Each value represents the mean of transgene expression per well in relative light units (RLU) from five independent experiments +/- SD.

Human MT

Transduction of primary myotubes (MTs) with Ad5EGFP and Ad19a/64-EGFP. Ten-day-old myotubes were transduced with 1250 VP/cell (open columns). 2500 VP/cell (shaded columns) and 12500 VP/cell (solid columns), respectively. GFP expression was quantified after 48 hr. Each value represents the mean relative light units (RLU) of five independent transductions +/- SD.

Publications

Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. Neukirch L, Nielsen TK, Laursen H, Daradoumis J, Thirion C, Holst PJ.Oncotarget. 2019 Feb 15;10(14):1458-1472. doi: 10.18632/oncotarget.26680. eCollection 2019 Feb 15.

Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques. Ragonnaud E, Schroedel S, Mariya S, Iskandriati D, Pamungkas J, Fougeroux C, Daradoumis J, Thomsen AR, Neukirch L, Ruzsics Z, Salomon M, Thirion C, Holst PJ. Vaccine. 2018 Oct 1;36(41):6212-6222. doi: 10.1016/j.vaccine.2018.07.075. Epub 2018 Sep 3.

Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Lapuente D, Ruzsics Z, Thirion C, Tenbusch M.Vaccine. 2018 May 3;36(19):2712-2720. doi: 10.1016/j.vaccine.2018.02.075. Epub 2018 Apr 5.

Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo. Kiener R, Fleischmann M, Schwegler C, Ruzsics Z, Thirion C, Schrödel S, Asbach B, Wagner R. Sci Rep. 2018 Jan 24;8(1):1474. doi: 10.1038/s41598-018-19874-1.

Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Thirion C, Lochmüller H, Ruzsics Z, Boelhauve M, König C, Thedieck C, Kutik S, Geiger C, Kochanek S, Volpers C, Burgert HG. Hum Gene Ther. 2006 Feb;17(2):193-205.

Contact us to discover more